TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
Discover the latest trends in RNA-based therapeutics and learn how sponsors can successfully navigate the road to next generation innovation. Listen in as Citeline chats with the Director of Therapeutics at Novotech, a CRO experienced in RNA development.
An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.
